589 related articles for article (PubMed ID: 26138037)
41. Urine gamma-synuclein as a biomarker for the diagnosis of bladder cancer.
Liu C; Shi B; Hao C; Wang Q; Lv Q; Xing N; Shou J; Qu L; Gao Y; Qin C; Zhao J; Shou C
Oncotarget; 2016 Jul; 7(28):43432-43441. PubMed ID: 27223068
[TBL] [Abstract][Full Text] [Related]
42. UBE2C cell-free RNA in urine can discriminate between bladder cancer and hematuria.
Kim WT; Jeong P; Yan C; Kim YH; Lee IS; Kang HW; Kim YJ; Lee SC; Kim SJ; Kim YT; Moon SK; Choi YH; Kim IY; Yun SJ; Kim WJ
Oncotarget; 2016 Sep; 7(36):58193-58202. PubMed ID: 27528424
[TBL] [Abstract][Full Text] [Related]
43. Hypoxia-regulated carbonic anhydrase IX (CAIX) protein is an independent prognostic indicator in triple negative breast cancer.
Ong CHC; Lee DY; Lee B; Li H; Lim JCT; Lim JX; Yeong JPS; Lau HY; Thike AA; Tan PH; Iqbal J
Breast Cancer Res; 2022 Jun; 24(1):38. PubMed ID: 35659359
[TBL] [Abstract][Full Text] [Related]
44. Lowered oxygen tension induces expression of the hypoxia marker MN/carbonic anhydrase IX in the absence of hypoxia-inducible factor 1 alpha stabilization: a role for phosphatidylinositol 3'-kinase.
Kaluz S; Kaluzová M; Chrastina A; Olive PL; Pastoreková S; Pastorek J; Lerman MI; Stanbridge EJ
Cancer Res; 2002 Aug; 62(15):4469-77. PubMed ID: 12154057
[TBL] [Abstract][Full Text] [Related]
45. Evaluation of carbonic anhydrase IX as a potential therapeutic target in urothelial carcinoma.
Todenhöfer T; Gibb EA; Seiler R; Kamyabi A; Hennenlotter J; McDonald P; Moskalev I; Stewart C; Gao J; Fazli L; Dedhar S; Stenzl A; Oo HZ; Black PC
Urol Oncol; 2021 Aug; 39(8):498.e1-498.e11. PubMed ID: 34083096
[TBL] [Abstract][Full Text] [Related]
46. Carbonic anhydrase IX expression predicts outcome of interleukin 2 therapy for renal cancer.
Atkins M; Regan M; McDermott D; Mier J; Stanbridge E; Youmans A; Febbo P; Upton M; Lechpammer M; Signoretti S
Clin Cancer Res; 2005 May; 11(10):3714-21. PubMed ID: 15897568
[TBL] [Abstract][Full Text] [Related]
47. Urinary bladder cancer test: a new urinary tumor marker in the follow-up of superficial bladder cancer.
Mungan NA; Vriesema JL; Thomas CM; Kiemeney LA; Witjes JA
Urology; 2000 Nov; 56(5):787-92. PubMed ID: 11068302
[TBL] [Abstract][Full Text] [Related]
48. The role of carbonic anhydrase IX as a molecular marker for transitional cell carcinoma of the bladder.
Klatte T; Belldegrun AS; Pantuck AJ
BJU Int; 2008 Jun; 101 Suppl 4():45-8. PubMed ID: 18430124
[No Abstract] [Full Text] [Related]
49. Comparative diagnostic value of urine cytology, UBC-ELISA, and fluorescence in situ hybridization for detection of transitional cell carcinoma of urinary bladder in routine clinical practice.
May M; Hakenberg OW; Gunia S; Pohling P; Helke C; Lübbe L; Nowack R; Siegsmund M; Hoschke B
Urology; 2007 Sep; 70(3):449-53. PubMed ID: 17688921
[TBL] [Abstract][Full Text] [Related]
50. UBC
Ecke TH; Weiß S; Stephan C; Hallmann S; Barski D; Otto T; Gerullis H
Tumour Biol; 2017 May; 39(5):1010428317701624. PubMed ID: 28468590
[TBL] [Abstract][Full Text] [Related]
51. Diagnostic and prognostic value of bladder cancer-related transcript markers in urine.
Schmidt J; Propping C; Siow WY; Lohse-Fischer A; Toma M; Baldauf-Twelker A; Hakenberg OW; Wirth MP; Fuessel S
J Cancer Res Clin Oncol; 2016 Feb; 142(2):401-14. PubMed ID: 26328914
[TBL] [Abstract][Full Text] [Related]
52. Carbonic anhydrase IX (CAIX) as a mediator of hypoxia-induced stress response in cancer cells.
McDonald PC; Dedhar S
Subcell Biochem; 2014; 75():255-69. PubMed ID: 24146383
[TBL] [Abstract][Full Text] [Related]
53. Carbonic anhydrase IX, a marker of hypoxia: correlation with clinical outcome in transitional cell carcinoma of the bladder.
Hussain SA; Palmer DH; Ganesan R; Hiller L; Gregory J; Murray PG; Pastorek J; Young L; James ND
Oncol Rep; 2004 May; 11(5):1005-10. PubMed ID: 15069539
[TBL] [Abstract][Full Text] [Related]
54. Preliminary evaluation of urinary soluble Met as a biomarker for urothelial carcinoma of the bladder.
McNeil BK; Sorbellini M; Grubb RL; Apolo A; Cecchi F; Athauda G; Cohen B; Giubellino A; Simpson H; Agarwal PK; Coleman J; Getzenberg RH; Netto GJ; Shih J; Linehan WM; Pinto PA; Bottaro DP
J Transl Med; 2014 Oct; 12():199. PubMed ID: 25335552
[TBL] [Abstract][Full Text] [Related]
55. Prognostic value of carbonic anhydrase IX immunohistochemical expression in renal cell carcinoma: a meta-analysis of the literature.
Zhao Z; Liao G; Li Y; Zhou S; Zou H; Fernando S
PLoS One; 2014; 9(11):e114096. PubMed ID: 25426861
[TBL] [Abstract][Full Text] [Related]
56. DNA damage is a prerequisite for p53-mediated proteasomal degradation of HIF-1alpha in hypoxic cells and downregulation of the hypoxia marker carbonic anhydrase IX.
Kaluzová M; Kaluz S; Lerman MI; Stanbridge EJ
Mol Cell Biol; 2004 Jul; 24(13):5757-66. PubMed ID: 15199132
[TBL] [Abstract][Full Text] [Related]
57. Prospective evaluation of serum tissue inhibitor of metalloproteinase 1 and carbonic anhydrase IX in correlation to circulating tumor cells in patients with metastatic breast cancer.
Müller V; Riethdorf S; Rack B; Janni W; Fasching PA; Solomayer E; Aktas B; Kasimir-Bauer S; Zeitz J; Pantel K; Fehm T;
Breast Cancer Res; 2011 Jul; 13(4):R71. PubMed ID: 21745383
[TBL] [Abstract][Full Text] [Related]
58. The diagnostic value of cytohistological urine analysis and cytokeratin 20 in malignant and atypical urothelial cells.
Negri S; Biavati P; Bondi A
Pathologica; 2016 Sep; 108(3):130-135. PubMed ID: 28195264
[TBL] [Abstract][Full Text] [Related]
59. GLUT1 and CAIX as intrinsic markers of hypoxia in bladder cancer: relationship with vascularity and proliferation as predictors of outcome of ARCON.
Hoskin PJ; Sibtain A; Daley FM; Wilson GD
Br J Cancer; 2003 Oct; 89(7):1290-7. PubMed ID: 14520462
[TBL] [Abstract][Full Text] [Related]
60. Diagnostic value of metabolic phenotypes in malignant pleural effusions: expression of GLUT1 and CAIX by immunocytochemistry.
Liao ND; Shieh JM; Lee WY
Cancer Cytopathol; 2011 Oct; 119(5):346-53. PubMed ID: 21442770
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
